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Sterol regulatory element-binding proteins (SREBPs) are major transcription factors that regulate
the expression of genes involved in fatty acid and cholesterol biosynthesis. Here we show that 40-
hydroxyﬂavanone (40-HF) impairs the fatty acid synthase promoter activity and reduces the activa-
tion of SREBPs and their target gene expression in human hepatoma Huh-7 cells. Moreover, 40-HF
suppresses de novo fatty acid and cholesterol synthesis. This study identiﬁes 40-HF as an inhibitor
of SREBP maturation and lipid synthesis, and provides evidence that 40-HF may have major potential
as a pharmaceutical preparation against hepatic steatosis and dyslipidemia.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The prevalence of hepatic steatosis is increasing rapidly in
developed countries [1]. Obesity and insulin resistance are the
most prevailing risk factors for hepatic steatosis which is caused
by an imbalance between triglyceride acquisition and removal. In
the absence of efﬁcacious therapeutic options, hepatic steatosis
causes progressive cirrhosis and liver cancer. Hence, new drugs
to treat hepatic steatosis need to be developed.
Sterol regulatory element-binding proteins (SREBPs) are a fam-
ily of transcription factors comprising SREBP-1a, SREBP-1c, and
SREBP-2, which regulate the transcription of genes related to fatty
acid and cholesterol biosynthesis [2]. SREBPs are synthesized as
precursor proteins that are inserted into the ER membrane and
processed to liberate the N-terminal halves, which function as
transcription factors in the nucleus. Insulin increases hepatic lipo-
genesis which is largely mediated by the activation of SREBP-1c at
the levels of transcription and proteolytic processing [3–5]. In the
liver of many insulin-resistant mouse models, insulin fails to
reduce gluconeogenesis though it still promotes lipogenesis
accompanied by elevated levels of SREBP-1c [6]. The dysregulation
of SREBP-1c has been implicated in the pathogenesis of hepatic
steatosis and dyslipidemia [7,8].
In this study, to ﬁnd small molecules that inhibit SREBP activity,
we established Huh-7 cells that stably express a luciferase genechemical Societies. Published by E
unkyo-ku, Tokyo 113-8657,
. Sato).under the control of the human fatty acid synthase (FAS) promoter,
which contains SREBP-binding elements. Using these cells, we
found that 40-HF, a synthetic analogue of ﬂavanone, attenuates
SREBP activities. We also found that 40-HF inhibits proteolytic pro-
cessing of SREBPs, and these inhibitions are followed by the sup-
pression of de novo fatty acid and cholesterol synthesis.
2. Materials and methods
2.1. Reagents
Flavanone, 25-hydroxycholesterol (25-HC), ﬂuvastatin, and lipo-
protein-deﬁcient serum (LPDS) were purchased from Sigma. 20-
Hydroxyﬂavanone and 40-hydroxyﬂavanone were purchased from
extrasynthese. 30-Hydroxyﬂavanone and DMEM were purchased
from Wako.
2.2. Cell culture
Huh-7 cells were maintained in medium A (DMEM supple-
mented with 100 units/mL penicillin and 100 lg/mL streptomycin
containing 10% FBS). Huh-7/FAS-Luc cells were maintained in med-
ium A containing 2 lg/mL blasticidin S. The cells were incubated at
37 C under a 5% CO2 atmosphere.
2.3. Plasmid construct
A luciferase reporter plasmid, pFAS-Luc, was constructed by
cloning BglII–HindIII PCR fragments coding the 50-untranslatedlsevier B.V. All rights reserved.
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pGL4.10 vector (Promega). pFAS-Luc contains the FAS promoter
from 987 to +121.
2.4. Stable transfection of Huh-7 cells with the FAS promoter-
containing luciferase reporter plasmid
Huh-7 cells were plated in 60-mm dishes at a density of 8  105
cells/dish and cultured with medium A for 20 h. They were subse-
quently transfected with 7.62 lg of pGL4-FAS, a reporter plasmid
containing the FAS promoter, and 0.38 lg of pMAM2-BSD, an
expression plasmid for blasticidin S deaminase [9], by lipofect-
amine 2000 according to the manufacturer’s instructions.
Twenty-four hours after transfection, the cells were plated in
100-mm dishes and cultured with medium A containing 8 lg/mL
blasticidin S. The medium was changed every 2nd day until well-
deﬁned colonies were evident. Colonies were isolated with cloning
cylinders in the presence of 2 lg/mL blasticidin S. The resulting
stable cell lines were cultured with medium B [DMEM supple-
mented with 100 units/mL penicillin, 100 lg/mL streptomycin, a
12.5 lM concentration of a HMG CoA reductase inhibitor (ﬂuvast-
atin), and 50 lM sodium mevalonate containing 5% LPDS] under
sterol-depleted conditions for 16 h. They were then sequentially
cultured in the absence or presence of 1 lg/mL 25-HC for 24 h.
The cell line that showed the greatest suppression of luciferase
activity by 25-HC was selected and designated Huh-7/FAS-Luc.
2.5. Luciferase assays using an Huh-7/FAS-Luc cell line
Huh-7/FAS-Luc cells were plated in 12-well plates at a density
of 1  105 cells/well, cultured with medium A for 20 h, and then
the cells were switched to medium C (medium A supplemented
with 12.5 lM ﬂuvastatin and 50 lM sodium mevalonate) for
16 h. After incubation for another 24 h in the absence or presence
of 100 lM of the test compound, luciferase activity and protein
content in the cell extracts were measured as described previously
[10]. Normalized luciferase values were determined by dividing
the luciferase activity by the protein contents in the cell extracts.
2.6. Real-time PCR
Huh-7 cells were plated in 6-well plates at a density of 5  105
cells/well and cultured withmedium A for 20 h. The cells were then
switched to medium B for 16 h. After incubation for another 24 h in
the absence or presence of 100 lM 40-HF, total RNA was extracted
from Huh-7 cells using Isogen (Wako) according to the manufac-
turer’s instructions. cDNA was synthesized and ampliﬁed from
2 lg of total RNA using a high capacity cDNA reverse transcription
kit (Applied Biosystems). Quantitative real-time PCR (Taqman
probe and SYBR green) analysis was performed on an Applied
Biosystems StepOnePlus instrument. Expression was normalized
to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) control.
The TaqMan ID number for genes analyzed are as follows: FAS,
Hs00188012_m1; Stearoyl-CoA Desaturase 1 (SCD1), Hs00748952_
s1; and GAPDH, 4352934. The sequences of the primers for
HMG-CoA synthase are 50-GACTTGTGCATTCAAACATAGCAA-30 and
50-GCTGTAGCAGGGAGTCTTGGTACT-30, those for HMG-CoA Reduc-
tase are 50-TACCATGTCAGGGGTACGTC-30 and 50-AAGCCTAGAG
ACATAATCATC-30, and those for acyl-CoA synthetase long-chain
family member 3 (ACSL3) are 50-CCCCTGAAACTGGTCTGGTG-30
and 50-TCCGCCTGGTAATGTGTTTTAA-30.
2.7. Antibodies
Monoclonal anti-SREBP-1 (2A4) and anti-SREBP-2 (1C6) anti-
bodies were obtained from Santa Cruz. Monoclonal anti-b-actin(AC-15) antibody was purchased from Sigma. The anti-SREBP-2
polyclonal antibody (Rs004) has been described previously [11].
Peroxidase-conjugated afﬁnity-puriﬁed goat anti-rabbit IgG and
goat anti-mouse IgG were purchased from Jackson Immunore-
search Laboratories.
2.8. Immunoblotting
Huh-7 cells were plated in 6-well plates at a density of 5  105
cells/well and cultured with medium A for 20 h. The cells were
then switched to medium B in the absence or presence of
100 lM 40-HF for 3 or 6 h. The cells were lysed in RIPA buffer
(50 mM Tris–HCl, pH 8.0, 150 mM sodium chloride, 0.1% SDS,
0.5% deoxycholate, and 1% Triton X-100) supplemented with prote-
ase inhibitors. The lysates were subjected to SDS–PAGE, trans-
ferred onto a PVDF membrane, and probed with the antibodies
indicated in the ﬁgure legends. Immunoreactive proteins were
visualized using ECL (GE Healthcare) or Immobilon (Millipore)
Western blotting detection reagents. The signals on the membrane
were detected by a LAS-3000 Luminoimager (Fujiﬁlm).
2.9. Determination of cholesterol and FA synthesis rates
Huh-7 cells were plated in 12-well plates at a density of 2  105
cells/well and cultured with medium A for 20 h. The cells were
then switched to medium D (DMEM supplemented with
100 units/mL penicillin and 100 lg/mL streptomycin containing
5% LPDS) for 16 h. After incubation for another 18 h in the absence
or presence of 100 lM40-HF, the cells were placed in fresh medium
supplemented with [14C]acetate (1.6 lCi/mL) and incubated for
6 h. The cells were washed, scraped, and collected by centrifuga-
tion. The pelleted cells were mixed with 1 mL 8 N potassium hy-
drate and 1 mL ethanol per well. The mixture was heated at
100 C for 2 h and extracted twice with 2 mL of petroleum ether
(cholesterol extract). Two milliliters of the lower aqueous layer
was initially mixed with 1 mL of 12 N hydrochloric acid and then
extracted twice with 3 mL of petroleum ether (FA extract) [12].
The lipid extracts were resolved by thin-layer chromatography
(Silica gel 60, Merck) and quantiﬁed with a BAS2000 image analy-
sis system (Fujiﬁlm). Normalized cholesterol and FA synthesis
rates were determined by dividing the signals of [14C]-cholesterol
and [14C]-FA by the amounts of total cellular protein determined
by the BCA protein assay (Pierce).
2.10. Statistical analysis
All data are presented as mean ± SEM. Statistical analysis was
performed using StatView software. Student’s t-test was used to
compare pairs of groups. Differences were considered signiﬁcant
at p < 0.05.3. Results
3.1. 40-HF suppresses the promoter activity of the FAS gene
To identify compounds that suppress SREBP activity, we estab-
lished a stable cell line that expresses a luciferase reporter gene
under the control of a FAS promoter that is driven by SREBP. Hu-
man hepatoma Huh-7 cells were transfected with pFAS-Luc to-
gether with the expression plasmid for blasticidin S deaminase,
and then incubated in a medium containing blasticidin S. The
clones resistant to blasticidin S were isolated, expanded, and des-
ignated the Huh-7/FAS-Luc cells. SREBP activity can be monitored
by luciferase levels using this cell line, since luciferase activities
of Huh-7/FAS-Luc cells were diminished by treatment with
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the course of identifying compounds that suppress SREBP activity,
we identiﬁed 40-HF as a potent inhibitor of FAS promoter activity
(Fig. 1B). Interestingly, ﬂavanone and other ﬂavanone derivatives
including 20-HF and 30-HF did not decrease, but rather slightly in-
creased luciferase activity in Huh-7/FAS-Luc cells (Fig. 1B).mature 
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03.2. 40-HF inhibits SREBP processing
To investigate the effect of 40-HF on SREBP proteolytic process-
ing, Huh-7 cells were treated with 40-HF for 3 or 6 h. SREBP-1 was
detected by an antibody recognizing its N-terminus [SREBP-1(N)],
and SREBP-2 was detected by antibodies recognizing its N-termi-
nus [SREBP-2(N)] as well as C-terminus [SREBP-2(C)]. Consistent
with a previous report [13], SREBP processing was reduced by
25-HC, as estimated by the decreased amounts of its mature and
cleaved forms (Fig. 2). 40-HF suppressed SREBP processing within
3 h of its application and this inhibitory effect continued up to
6 h (Fig. 2). It should be noted that the amount of the mature form
of SREBP-2 [SREBP-2(N)] was reduced by 40-HF to the same degree
as by 25-HC, whereas the reduction of the cleaved form of SREBP-2
[SREBP-2(C)] differed between 40-HF and 25-HC.B
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Fig. 1. 40-HF suppresses the promoter activity of the FAS gene. (A) Structures of the
ﬂavanones used in this study. (B) Luciferase activity in the presence of 100 lM test
compound or 1 lg/mL 25-hydroxycholesterol (25-HC). Luciferase activity in the
presence of the vehicle is represented as 100 (B). All results are expressed as
mean ± SEM, n = 3. ⁄p < 0.05, ⁄⁄p < 0.01.
Fig. 2. 4 -HF suppresses the processing of SREBP-1 and SREBP-2. Whole cell extracts
were subjected to SDS/PAGE and immunoblotting (IB) with anti-SREBP-1(N) (2A4),
anti-SREBP-2(N) (Rs004), anti-SREBP-2(C) (1C6), or anti-b-actin antibodies. The
same results were obtained in more than three separate experiments.3.3. 40-HF suppresses the expression of SREBP target genes and de novo
fatty acid and cholesterol synthesis
To examine whether 40-HF causes a decrease in the endogenous
mRNA levels of SREBP targets, Huh-7 cells were treated with 40-HF
for 24 h. Quantitative real-time PCR analyses revealed that 40-HF
treatment caused a signiﬁcant decrease in the mRNA levels of
SREBP targets including HMG-CoA synthase, HMG-CoA reductase,
FAS, and SCD1 but not ACSL3 which is not an SREBP target
(Fig. 3). Consistent with these changes in gene expression, 40-HF
treatment signiﬁcantly decreased de novo fatty acid and choles-
terol synthesis (Fig. 4).
4. Discussion
The present study demonstrates that 40-HF suppresses the pro-
moter activity of the FAS gene in Huh-7/FAS-Luc cells. Biochemical
analyses further reveal that decreased SREBP processing in re-
sponse to 40-HF treatment suppresses endogenous SREBP target
gene expression and de novo fatty acid and cholesterol synthesis
in Huh-7 cells.
SREBP proteolytic processing is tightly regulated by the interac-
tion between two ER membrane proteins, the SREBP cleavage-acti-
vating protein (SCAP), and the insulin-inducing gene (Insig). When
cells are depleted of sterols, SCAP escorts SREBPs from the ER to the
Golgi. Thereafter, SREBPs are processed by two proteases, site-1
protease and site-2 protease, within the Golgi. Once the ER mem-
brane cholesterol content increases, SCAP binds to cholesterol, in-
duces conformational changes, binds to Insig, and thereby
remains on the ERmembrane [14]. To date, several small molecules
other than cholesterol have been reported to inhibit SREBP process-
ing. Betulin, a naturally occurring pentacyclic triterpene, and oxys-
terols act by binding to SCAP and Insig, respectively, and
consequently stimulate the interaction between SCAP and Insig
[13,15]. Polyunsaturated fatty acids and the diarylthiazole deriva-
tive fatostatin are known to impair SREBP processing [16,17]. How-
ever, the mechanism by which these molecules inhibit SREBP
processing is currently unknown. In the present study, we
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Fig. 3. 40-HF suppresses the gene expression of SREBP targets. Relative mRNA levels
were obtained after normalization to GAPDH mRNA. The mRNA levels with vehicle
treatment are represented as 1. All results are expressed as mean ± SEM, n = 3.
⁄p < 0.05, ⁄⁄p < 0.01.
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Fig. 4. 40-HF suppresses de novo fatty acid and cholesterol synthesis. The
incorporation of [14C]acetate into newly synthesized fatty acids (A) and cholesterol
(B) was determined.
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the decline in the cleaved form of SREBP-2 [SREBP-2(C)] by 40-HF
was weak in comparison with that of the mature form of SREBP-2
[SREBP-2(N)]. These results suggest the possibility that 40-HF stabi-
lizes the cleaved form of SREBP-2 in addition to inhibiting SREBP
processing. Given that 40-HF hinders processing of both SREBP-1
and SREBP-2 to the same degree, it may be important for common
factor(s) such as SCAP or Insig that are involved in SREBP process-
ing. It is also probable that 40-HF modulates certain intracellular
protein kinase signaling pathways, which in turn affect SREBP pro-
cessing. A plausible candidate is AMPK because it has been reported
to phosphorylate SREBPs and attenuate SREBP processing [18].
However, at present, it is largely unknown whether 40-HF inﬂu-
ences any intracellular protein kinase activities. Further studies
are required to elucidate a link between 40-HF and SREBP
processing.
We found that 40-HF, but not ﬂavanone or the ﬂavanone deriv-
atives 20-HF and 30-HF, suppresses SREBP activity. These resultsindicate that the presence of a 40-hydroxyl group of ﬂavanone is
essential for this suppressive effect. It has also been reported that
40-HF exhibits several biological activities such as decreasing colla-
gen synthesis in human ﬁbroblasts [19] and vasorelaxing effects in
isolated rat aortic ring [20]. However, the 40-hydroxyl group of ﬂa-
vanone is unlikely to be essential for these activities since ﬂava-
none and 6-HF also exhibit a similar effect on collagen synthesis
and vasorelaxing activity, respectively [19,20]. These ﬁndings im-
ply that 40-HF exerts these biological effects via several distinct
pathways.
We established Huh-7/FAS-Luc cells using the promoter region
of the human FAS gene (987 to +121) that contains a number of
DNA sequence motifs speciﬁc for LXR, Sp1, and NF-Y [21]. Thus, it
is possible that 40-HF attenuates FAS gene expression by impairing
any of these transcription factors in addition to SREBPs. However,
since 40-HF did not affect the expression of the ACSL3 gene, which
is a LXR target gene [22], altered LXR activity is unlikely to be in-
volved in a 40-HF-dependent decrease in FAS gene expression.
In conclusion, using our novel assay system with Huh-7/FAS-
Luc cells, we identiﬁed 40-HF as an inhibitor of SREBP processing
and de novo fatty acid and cholesterol synthesis. Further studies
are necessary to determine the molecular mechanism of 40-HF ac-
tion. This study provides evidence that 40-HF may have major po-
tential as a pharmaceutical preparation against hepatic steatosis
and dyslipidemia.Acknowledgements
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